Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Metz

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Journal of Medicinal Chemistry|August 3, 2018
Mathematical and Structural Characterization of Strong Nonadditive Structure-Activity Relationship Caused by Protein Conformational ChangesLaurent Gomez, Rui Xu, William Sinko, et al.
Journal of the American Chemical Society|September 28, 2011
Prospective CCR5 small molecule antagonist compound design using a combined mutagenesis/modeling approachMarkus Metz, Elyse Bourque, Jean Labrecque, et al.
Virology|March 11, 2011
HIV-1 entry inhibition by small-molecule CCR5 antagonists: a combined molecular modeling and mutant study using a high-throughput assayJean Labrecque, Markus Metz, Gloria Lau, et al.
Bioorganic & Medicinal Chemistry Letters|April 22, 2011
The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitorsYibin Xiang, Bradford Hirth, Gary Asmussen, et al.
Journal of Medicinal Chemistry|January 2, 2010
Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replicationGary J Bridger, Renato T Skerlj, Pedro E Hernandez-Abad, et al.
Bioorganic & Medicinal Chemistry Letters|March 15, 2011
Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replicationRenato Skerlj, Gary Bridger, Yuanxi Zhou, et al.
Journal of Medicinal Chemistry|February 21, 2012
Implications of promiscuous Pim-1 kinase fragment inhibitor hydrophobic interactions for fragment-based drug designAndrew C Good, Jinyu Liu, Bradford Hirth, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 ReplicationRenato Skerlj, Gary Bridger, Yuanxi Zhou, et al.
ACS Medicinal Chemistry Letters|May 15, 2024
Identification of Selective Imidazopyridine CSF1R InhibitorsJohn L Kane, Gary Asmussen, Joseph Batchelor, et al.
Scientific Data|August 2, 2016
Serial femtosecond crystallography datasets from G protein-coupled receptorsThomas A White, Anton Barty, Wei Liu, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Journal of Medicinal Chemistry|August 3, 2018
Mathematical and Structural Characterization of Strong Nonadditive Structure-Activity Relationship Caused by Protein Conformational ChangesLaurent Gomez, Rui Xu, William Sinko, et al.
Journal of the American Chemical Society|September 28, 2011
Prospective CCR5 small molecule antagonist compound design using a combined mutagenesis/modeling approachMarkus Metz, Elyse Bourque, Jean Labrecque, et al.
Virology|March 11, 2011
HIV-1 entry inhibition by small-molecule CCR5 antagonists: a combined molecular modeling and mutant study using a high-throughput assayJean Labrecque, Markus Metz, Gloria Lau, et al.
Bioorganic & Medicinal Chemistry Letters|April 22, 2011
The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitorsYibin Xiang, Bradford Hirth, Gary Asmussen, et al.
Journal of Medicinal Chemistry|January 2, 2010
Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replicationGary J Bridger, Renato T Skerlj, Pedro E Hernandez-Abad, et al.
Bioorganic & Medicinal Chemistry Letters|March 15, 2011
Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replicationRenato Skerlj, Gary Bridger, Yuanxi Zhou, et al.
Journal of Medicinal Chemistry|February 21, 2012
Implications of promiscuous Pim-1 kinase fragment inhibitor hydrophobic interactions for fragment-based drug designAndrew C Good, Jinyu Liu, Bradford Hirth, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 ReplicationRenato Skerlj, Gary Bridger, Yuanxi Zhou, et al.
ACS Medicinal Chemistry Letters|May 15, 2024
Identification of Selective Imidazopyridine CSF1R InhibitorsJohn L Kane, Gary Asmussen, Joseph Batchelor, et al.
Scientific Data|August 2, 2016
Serial femtosecond crystallography datasets from G protein-coupled receptorsThomas A White, Anton Barty, Wei Liu, et al.
Pageof 5